Abstract
Background:Epigenetic changes are encountered in acute myeloid leukemia (AML) and are thought to contribute to leukemogenesis. Decreased histone acetylation was frequently found in AML, especially in high‐risk cytogenetics, higher age, secondary or relapsed/refractory AML. HDAC inhibitors have been found to be effective in AML. But the data was limited in China.Aims:This retrospective study evaluated the clinical outcomes of chidamide combined with FLAG regimen for relapsed/refractory AML in our single center.Methods:From May 2018 to December 2018, 12 patients with relapsed/refractory AML including 6 AML/ETO positive received induction chemotherapy of “chidamide +FLAG” regimen (chidamide 30 mg/d twice a week for two weeks, fludarabine 30 mg/m2/ d for 5 days, Ara‐C 2 g/m2 /d for 5 days, G‐CSF 5‐10ug/kg/d continuedly until neutrophil recoverd).Results:A total of 7 patients achieved a complete remission (CR) after induction chemotherapy (CR rate 58.3%). In 6 AML/ETO positive patients, 5 patients achieved molecular remission (CR rate 83.3%). At the end of the follow‐up period, 8 patients underwent hematopoietic stem cell transplantation and 7 patients survived in CR.Summary/Conclusion:Chidamide might be suitable drugs in relapsed/refractory AML therapy, especially in AML/ETO positive patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
